Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin

Genentech's Avastin may not have produced a storybook ending in metastatic breast cancer, but it still serves as an example of how the accelerated approval process can work

More from Archive

More from Pink Sheet